Wangzhen He, Liangliang Xu, Jiongyan Ding, Li Song, Weili Yang, Isabella Klooster, Daniel F Pilco-Janeta, César Serrano, Hongming Fang, Guojun Jiang, Xiaoyan Wang, Jiren Yu, Wen-Bin Ou
Most gastrointestinal stromal tumors (GIST) harbor mutated receptor tyrosine kinase (RTK) KIT/PDGFRA, which provides an attractive therapeutic target. However, a majority of GISTs ultimately develop resistance to KIT/PDGFRA inhibitor imatinib, multiple therapeutic targets will be identified as a reasonable strategy in imatinib-resistant GISTs. Biological mechanisms of non-RTK activated CDC42 associated kinase 1 (ACK1) are still unclear, which has been found to be activated in GISTs. In the current report, ACK1 overexpression is demonstrated in GIST cell lines and biopsies...
March 13, 2023: Biochimica et Biophysica Acta. Molecular Basis of Disease